Publications by authors named "Bruce McCall"

Claim this Profile
E
Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.
Franck Morschhauser, Gilles Salles, Laurie H Sehn, Alex F Herrera, Jonathan W Friedberg, Bruce McCall

J Clin Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.
Franck Morschhauser, Gilles Salles, Laurie H Sehn, Alex F Herrera, Jonathan W Friedberg, Bruce McCall

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials.
Mark D Stewart, Bruce McCall, Marcelo Pasquini, Allen S Yang, Carolyn D Britten

Cytotherapy· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors.
Colin D Weekes, Lee S Rosen, Anna Capasso, Kit Man Wong, Weilan Ye, Bruce McCall

Cancer Chemother Pharmacol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
Joachim von Pawel, David R Spigel, Thomas Ervin, György Losonczy, Fabrice Barlesi, Bruce McCall

Oncologist· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.
Asha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek, Robin Dobbins, Lisa Marshall, Bruce McCall

J Immunother Cancer· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line Wild-Type Metastatic Colorectal Cancer.
Andrew G Hill, Michael P Findlay, Matthew E Burge, Christopher Jackson, Pilar Garcia Alfonso, Bruce B McCall

Clin Cancer Res· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
Rocío García-Carbonero, Eric van Cutsem, Fernando Rivera, Jacek Jassem, Ira Gore, Bruce McCall

Oncologist· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS.
Christopher H Lieu, Manuel Hidalgo, Jordan D Berlin, Andrew H Ko, Andres Cervantes, Bruce McCall

Oncologist· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
Rocío García-Carbonero, Eric van Cutsem, Fernando Rivera, Jacek Jassem, Ira Gore, Bruce McCall

Oncologist· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
Antonio Jimeno, Jean-Pascal Machiels, Lori Wirth, Pol Specenier, Tanguy Y Seiwert, Bruce McCall

Cancer· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).
Jérôme Fayette, Lori Wirth, Cristina Oprean, Anghel Udrea, Antonio Jimeno, Bruce McCall

Front Oncol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and relevance of proteinuria in bevacizumab-treated patients: pooled analysis from randomized controlled trials.
Richard A Lafayette, Bruce McCall, Nicole Li, Laura Chu, Patricia Werner

Am J Nephrol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis